Therapeutic use of anti-CS1 antibodies
View Patent ↗The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1. A humanized IgG 1 monoclonal antibody or antigen-binding fragment, wherein said humanized IgG 1 monoclonal antibody or antigen-binding fragment binds to a protein encoded by SEQ ID NO: 1 and comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:41 and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 44.
2. A conjugate compound comprising the monoclonal antibody or antigen-binding fragment of claim 1 conjugated to a cytotoxic agent.
3. A pharmaceutical composition comprising a pharmaceutical carrier and the antibody or antigen-binding fragment of claim 1 .
4. A pharmaceutical composition comprising a pharmaceutical carrier and the conjugate compound of claim 2 .
5. A method of treating a plasma cell cancer, comprising administering to a patient in need thereof the pharmaceutical composition of claim 3 .
6. The method of claim 5 , wherein the plasma cell cancer is multiple myeloma.
7. A method of treating a plasma cell cancer, comprising administering to a patient in need thereof the pharmaceutical composition of claim 4 .
8. The method of claim 7 , wherein the plasma cell cancer is multiple myeloma.
9. The method of claim 5 or claim 6 , which further comprises administering to the patient an immunosuppressive drug.
10. The method of claim 9 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered over a series of treatments.
11. The method of claim 9 , wherein the humanized IgG 1 monoclonal antibody is administered after the immunosuppressive drug.
12. The method of claim 9 , wherein the humanized IgG 1 monoclonal antibody is administered in combination with the immunosuppressive drug.
13. The method of claim 5 or claim 6 , which further comprises administering to the patient an immunomodulator.
14. The method of claim 13 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered over a series of treatments.
15. The method of claim 13 , wherein the humanized IgG 1 monoclonal antibody is administered after the immunomodulator.
16. The method of claim 13 , wherein the humanized IgG 1 monoclonal antibody is administered in combination with the immunomodulator.
17. The method of claim 13 , which further comprises administering to the patient an immunosuppressive drug.
18. The method of claim 16 , wherein the humanized IgG 1 monoclonal antibody is administered after the immunosuppressive drug and the immunomodulator.
19. The method of claim 16 , wherein the humanized IgG 1 monoclonal antibody is administered in combination with the immunosuppressive drug and the immunomodulator.